Last reviewed · How we verify

Olaparib Treatment D

AstraZeneca · FDA-approved active Small molecule

Olaparib Treatment D is a PARP inhibitor Small molecule drug developed by AstraZeneca. It is currently FDA-approved for BRCA1/2-mutant metastatic breast cancer, BRCA1/2-mutant metastatic ovarian cancer, Platinum-sensitive relapsed ovarian cancer (maintenance therapy).

Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.

Olaparib (Lynparza) is a PARP inhibitor developed by AstraZeneca for BRCA-mutant and homologous recombination deficiency (HRD)-positive cancers. The drug works by inhibiting poly(ADP-ribose) polymerase, preventing DNA repair in tumors with defective homologous recombination pathways, leading to synthetic lethality. Approved indications span ovarian cancer (platinum-sensitive and resistant), breast cancer, pancreatic cancer, and prostate cancer across multiple treatment lines. Olaparib is a first-in-class PARP inhibitor and remains a cornerstone of precision oncology, with peak annual sales exceeding $1.5B globally. The drug has demonstrated clinical differentiation through both monotherapy and combination regimens (notably with bevacizumab in ovarian cancer), and ongoing trials explore expansion into additional solid tumors including bladder, lung, and adrenal cancers. Commercial significance is substantial given the large addressable market in BRCA-positive populations and the shift toward biomarker-driven treatment paradigms.

At a glance

Generic nameOlaparib Treatment D
SponsorAstraZeneca
Drug classPARP inhibitor
TargetPARP1, PARP2
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

PARP inhibitors block the repair of single-strand DNA breaks. In BRCA1/2-deficient cancers that lack homologous recombination repair, this leads to accumulation of DNA damage and synthetic lethality. Olaparib is effective as monotherapy in BRCA-mutant cancers and as maintenance therapy following chemotherapy in platinum-sensitive ovarian cancer.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Olaparib Treatment D

What is Olaparib Treatment D?

Olaparib Treatment D is a PARP inhibitor drug developed by AstraZeneca, indicated for BRCA1/2-mutant metastatic breast cancer, BRCA1/2-mutant metastatic ovarian cancer, Platinum-sensitive relapsed ovarian cancer (maintenance therapy).

How does Olaparib Treatment D work?

Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors.

What is Olaparib Treatment D used for?

Olaparib Treatment D is indicated for BRCA1/2-mutant metastatic breast cancer, BRCA1/2-mutant metastatic ovarian cancer, Platinum-sensitive relapsed ovarian cancer (maintenance therapy), HRD-positive metastatic ovarian cancer, Metastatic pancreatic cancer with BRCA mutations.

Who makes Olaparib Treatment D?

Olaparib Treatment D is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Olaparib Treatment D in?

Olaparib Treatment D belongs to the PARP inhibitor class. See all PARP inhibitor drugs at /class/parp-inhibitor.

What development phase is Olaparib Treatment D in?

Olaparib Treatment D is FDA-approved (marketed).

What are the side effects of Olaparib Treatment D?

Common side effects of Olaparib Treatment D include Anemia, Nausea, Fatigue, Vomiting, Diarrhea, Thrombocytopenia.

What does Olaparib Treatment D target?

Olaparib Treatment D targets PARP1, PARP2 and is a PARP inhibitor.

Related